New insider Douglass Brian Robb claimed ownership of 6,252 shares (SEC Form 3)
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 12/31/2025 |
3. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 6,252(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (2) | 05/07/2034 | Common Stock | 2,980 | $167.72 | D | |
| Stock Option (Right to Buy) | (3) | 05/07/2034 | Common Stock | 7,020 | $167.72 | D | |
| Explanation of Responses: |
| 1. Represent restricted stock units that were awarded to represent a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock. 4,000 of the restricted stock units were granted on May 7, 2024 and vest in equal installments over a five-year period with each such vesting date occurring on the anniversary of the grant date. 2,252 of the restricted stock units were granted on March 1, 2025 and vest in equal installments over a four-year period with each such vesting date occurring on the anniversary of the grant date. |
| 2. The stock option was granted on May 7, 2024 and vest in equal installments over a five-year period with such vesting date occurring on the anniversary of the grant date. 596 shares have vested and the remaining shares will vest in equal installments on May 7, 2026, May 7, 2027, May 7, 2028 and May 7, 2029. |
| 3. The stock option was granted on May 7, 2024 and vest in equal installments over a five-year period with such vesting date occurring on the anniversary of the grant date. 1,404 shares have vested and the remaining shares will vest in equal installments on May 7, 2026, May 7, 2027, May 7, 2028 and May 7, 2029. |
| Remarks: |
| Exhibit 24.1: Power of Attorney |
| /s/ Meghan Stapleton (Attorney in Fact) | 01/12/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||